Marlborough-based Boston Scientific Corp. (BSX) has received approval to sell its system designed to treat tremor disorders in the European Union, the company announced Wednesday.
The EU awarded CE Mark, a designation allowing products to move freely through the EU’s member countries, for BSX’s Vercise Deep Brain Stimulation (DBS) System. The system treats the most common form of tremor, known as essential tremor (ET), among other tremor disorders.
According to BSX, ET is 20 times more prevalent than Parkinson’s disease, and the company said its DBS system is the first to offer precise neural targeting, allowing doctors to customize therapy for their patients.
Launched in 2012, the DBS system is still undergoing clinical trials and is not yet available for sale in the U.S. In addition to Europe, it is available for sale in Israel, Australia, and some Latin American countries.
